433253-68-0 Usage
Functional groups
Thiourea derivative, allyl group, phenoxyphenyl group
Structure
The thiourea core has an allyl group attached to one nitrogen atom and a 4-phenoxyphenyl group attached to the other nitrogen atom.
Applications
a. Research and chemical synthesis
b. Potential selective inhibitor of photosystem II in plants
c. Studied for antitumor and antifungal properties
Toxicological properties
Not well understood, should be handled with caution in laboratory settings.
Check Digit Verification of cas no
The CAS Registry Mumber 433253-68-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,3,3,2,5 and 3 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 433253-68:
(8*4)+(7*3)+(6*3)+(5*2)+(4*5)+(3*3)+(2*6)+(1*8)=130
130 % 10 = 0
So 433253-68-0 is a valid CAS Registry Number.
InChI:InChI=1/C16H16N2OS/c1-2-12-17-16(20)18-13-8-10-15(11-9-13)19-14-6-4-3-5-7-14/h2-11H,1,12H2,(H2,17,18,20)
433253-68-0Relevant articles and documents
Synthesis and biological evaluation of arylthiourea derivatives with antitubercular activity
Luo, Rusong,Laitinen, Tuomo,Teng, Liyan,Nevalainen, Tapio,Lahtela-Kakkonen, Maija,Zheng, Baofu,Wang, Honghai,Poso, Antti,Zhang, Xuelian
, p. 640 - 650 (2013/08/23)
Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis (M. tuberculosis), and remains one of the most life-threatening plagues for public health in the world. The emergence of drug resistant strains of TB and co-infection with HIV has further complicated TB treatment. Here, the synthesis and characterizaton of a series of compounds were described, and these were followed by evaluating for their antibacterial activity against M. tuberculosis. Several novel arylthiourea derivatives exhibited excellent activity (lowest MIC=0.09 μg/ml) against M. tuberculosis including drug resistant strains of M. tuberculosis. The results suggest that these compounds are promising candidates for new anti-TB agent development.
